HIV Diagnostics Market 2030 | Research Report, Analysis. Size, Share and Forecast
HIV Diagnostics Market Report Overview:
The global HIV
diagnostics market is projected to expand at a CAGR of approximately
10% over the forecast period. Market growth is being fueled by the rising
global prevalence of HIV, supportive government programs, increased awareness
around the importance of early detection, and the growing use of rapid
self-testing kits and point-of-care diagnostic solutions.
Download Sample PDF: https://meditechinsights.com/hiv-diagnostics-market/request-sample/
Despite this momentum, the adoption of HIV testing continues to face
challenges. High costs associated with advanced diagnostic technologies,
inadequate healthcare infrastructure in low- and middle-income countries, and
persistent social stigma surrounding HIV remain significant barriers to broader
market penetration.
HIV diagnostics encompass a range of methods used to detect the presence of
the Human Immunodeficiency Virus (HIV). Timely and accurate diagnosis is
essential not only for initiating the right treatment but also for preventing
further transmission within communities. Key HIV diagnostic methods include:
·
Antibody Tests:
The most common initial screening tools, designed to detect antibodies produced
by the immune system in response to HIV infection.
·
Antigen/Antibody Combination
Tests: Also known as 4th-generation tests,
these detect both HIV antibodies and the p24 antigen—one of the earliest
markers of infection—allowing for faster identification compared to
antibody-only tests.
·
Nucleic Acid Tests
(NATs): Highly sensitive tests that detect the viral RNA in the
bloodstream. NATs are crucial for early diagnosis and for monitoring viral load
in individuals living with HIV.
·
Rapid Diagnostic Tests
(RDTs): Point-of-care tests that provide results within 20–30
minutes using blood or oral fluid samples. Their speed and simplicity make them
ideal for community outreach and mobile testing.
·
Self-Testing Kits:
At-home kits that allow individuals to collect their own samples and test
privately. These significantly improve accessibility and help reduce the stigma
associated with clinical testing environments.
Collectively, these diagnostics play a vital role in HIV prevention,
treatment, and long-term disease management by enabling timely intervention and
reducing transmission rates.
Competitive Landscape
The global HIV diagnostics market is highly competitive, featuring both
established companies and emerging innovators. Key players include:
·
Abbott Laboratories
·
F. Hoffmann-La Roche Ltd.
·
BioMérieux S.A.
·
Siemens Healthineers
·
Danaher Corporation
·
OraSure Technologies
·
Chembio Diagnostics Inc.
·
Becton, Dickinson and Company (BD)
·
Thermo Fisher Scientific Inc.
·
Hologic, Inc.
To strengthen their market position, companies are focusing on product
innovation, strategic partnerships, collaborations, and geographic expansion.
Download the PDF brochure to learn more about this report.
Government Initiatives &
Global Funding: Expanding Access to HIV Testing
Government programs and international funding initiatives are key drivers of
the HIV diagnostics market. Public health agencies worldwide are partnering
with governments to expand access to HIV testing through subsidized programs,
large-scale screening campaigns, and improved healthcare infrastructure.
Major efforts include:
·
PEPFAR (U.S.
President’s Emergency Plan for AIDS Relief): A landmark
initiative that has significantly increased global HIV testing and facilitated
millions of screenings worldwide.
·
The Global Fund:
Providing financial and operational support for HIV testing programs,
particularly in high-burden regions such as sub-Saharan Africa and Southeast
Asia.
·
National Government
Actions: Countries like South Africa and Brazil have integrated
HIV testing into routine public healthcare, expanding outreach through mobile
clinics and point-of-care technologies.
In addition to expanding access, governments are accelerating regulatory
approvals and funding research and innovation to promote more advanced HIV
diagnostic technologies.
Examples of recent developments include:
·
Dec 2024:
The Global Fund and PEPFAR launched a coordinated effort to supply lenacapavir,
a long-acting injectable PrEP, to 2 million people over three years. This
initiative is supported by the Children’s Investment Fund Foundation and the
Bill & Melinda Gates Foundation.
·
Jan 2024:
The Global Fund approved US$9.2 billion in new
grants for HIV and other disease-related testing and awareness programs across
more than 70 countries—aimed at strengthening healthcare systems and expanding
access to essential diagnostics.
Download Sample PDF: https://meditechinsights.com/hiv-diagnostics-market/request-sample/
From Clinics to Comfort: The
Rapid Shift Toward HIV Self-Testing
HIV self-testing has grown rapidly in recent years, propelled by
technological advancements and a stronger emphasis on privacy, convenience, and
accessibility. Modern self-test kits—such as those using oral swabs—provide
results in about 20 minutes with high accuracy, reducing the discomfort
associated with blood-based tests.
Governments and global health organizations now increasingly integrate
self-testing into public health strategies to improve early detection and
reduce stigma. Offering individuals the ability to test privately at home has
proven especially impactful for populations hesitant to visit clinics.
Browse Research Report: https://meditechinsights.com/hiv-diagnostics-market/
Notable milestones include:
·
Jan 2025:
OraSure Technologies received FDA approval for the OraQuick HIV Self-Test
for individuals aged 14 and older, expanding youth access in the U.S.
·
Jun 2023:
Newfoundland Diagnostics partnered with Atomo Diagnostics to supply HIV rapid
self-test kits in retail stores such as Tesco across the UK/EU—the first
mainstream retail rollout in Europe.
·
Apr 2023:
Abbott partnered with Population Services International (PSI) to offer low-cost
HIV self-test kits in low- and middle-income countries, helping reduce stigma
and increase accessibility.
HIV Diagnostics Market –
Segmentation
This report by Medi-Tech Insights provides the size
of the global HIV diagnostics market at the regional- and country-level
from 2023 to 2030. The report further segments the market based on product,
test type, and end user.
Market Size &
Forecast (2023-2030), By Product, USD Million
·
o Reagents & Consumables
o Instruments/Devices
o Software & Services
Market Size &
Forecast (2023-2030), By Test Type, USD Million
·
o Antibody Tests
o Antigen/Antibody Combination Tests
o Nucleic Acid Tests (NAT)
o Viral Load Testing
o Other
Market Size &
Forecast (2023-2030), By End-user, USD Million
·
o Hospitals & Clinics
o Diagnostic Laboratories
o Home Care Setting
o Research Institutes
o Blood Banks
Market Size & Forecast
(2023-2030), By Region, USD Million
·
North America
o US
o Canada
·
Europe
o UK
o Germany
o France
o Italy
o Spain
o Rest of Europe
·
Asia Pacific
o China
o India
o Japan
o Rest of Asia Pacific
·
Latin America
·
Middle East & Africa
Related Report:
Microbiology Culture Market https://www.pharmiweb.com/press-release/2026-02-10/microbiology-culture-market-strategic-insights-and-growth-opportunities-with-key-players-and-forecast-to-2031
Varicose Vein Treatment Market https://www.pharmiweb.com/press-release/2026-02-10/varicose-vein-treatment-market-global-key-players-trends-share-market-size-segmentation-opportunities-forecast-to-2030
Urology Ultrasound Devices Market https://www.pharmiweb.com/press-release/2026-02-10/urology-ultrasound-devices-market-size-trends-report-segmented-by-type-size-share-and-forecast-to-2030
Healthcare Digital Twin Market https://www.pharmiweb.com/press-release/2026-02-10/healthcare-digital-twin-market-analysis-2030-technology-applications-and-impact-and-forecast
AI-based Clinical Trials Solution Provider Market https://www.pharmiweb.com/press-release/2026-02-10/ai-based-clinical-trials-solution-provider-market-2026-poised-for-innovation-and-global-expansion-through-2030
About Medi-Tech Insights;
Medi-Tech Insights is a healthcare-focused business research
& insights firm. Our clients include Fortune 500 companies, blue-chip
investors & hyper-growth start-ups. We have completed 100+ projects in
Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma
Services in the areas of market assessments, due diligence, competitive
intelligence, market sizing and forecasting, pricing analysis &
go-to-market strategy. Our methodology includes rigorous secondary research
combined with deep-dive interviews with industry-leading CXO, VPs, and key
demand/supply side decision-makers.
Contact:
Ruta Halde
Associate, Medi-Tech Insights
+32 498 86 80 79
Comments
Post a Comment